Source:http://linkedlifedata.com/resource/pubmed/id/15251373
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2004-7-14
|
pubmed:abstractText |
Organ transplant recipients display a high cardiovascular mortality rate. The type of immunosuppression has a major impact on cardiovascular risk factors (e.g., hypertension [HTN]). We assessed 24-hour blood pressure (BP) and metabolic profiles in a cohort of 106 long-term liver allograft recipients treated with either tacrolimus (Tac) or cyclosporine (CyA). The median age of patients was 50.8 years (range, 11 to 77) and the median time of follow-up was 65.4 months (ranges 12 to 168). Immunosuppression included low-dose steroids and either Tac (n = 46) or CyA (n = 60). Twenty-four-hour BP measurements revealed a significant difference in systolic BP (127.1 mmHg [94 to 163] Tac versus 132.7 mmHg [103 to 177] CyA; P <.03), and in mean arterial and diastolic blood pressures. In addition, the relative number of normotensive patients was significantly higher among Tac-treated patients (69.6% versus 34.8%). It is of note that the true incidence of HTN was higher after the number of patients with a pathological 24-h BP measurement was added to the initial number of patients already known to have HTN. No less than 76.4% of all long-term liver transplanted patients showed HTN. The results were unrelated to cumulative steroid dosage, frequency of antirejection therapy or underlying primary liver disease. In summary, immunosuppression-induced HTN is more common in CyA-treated than Tac-based regimens. Moreover, we found a substantial lack of detection of HTN in long-term liver transplant patients who received an insufficient quality of antihypertensive treatment. These findings have implications for the early diagnosis and treatment of HTN in liver transplant recipients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0041-1345
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2004 Elsevier Inc.
|
pubmed:issnType |
Print
|
pubmed:volume |
36
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1512-5
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15251373-Blood Pressure,
pubmed-meshheading:15251373-Blood Pressure Monitoring, Ambulatory,
pubmed-meshheading:15251373-Circadian Rhythm,
pubmed-meshheading:15251373-Cohort Studies,
pubmed-meshheading:15251373-Cross-Sectional Studies,
pubmed-meshheading:15251373-Cyclosporine,
pubmed-meshheading:15251373-Humans,
pubmed-meshheading:15251373-Immunosuppressive Agents,
pubmed-meshheading:15251373-Liver Transplantation,
pubmed-meshheading:15251373-Survivors,
pubmed-meshheading:15251373-Tacrolimus
|
pubmed:year |
2004
|
pubmed:articleTitle |
Blood pressure profile and treatment quality in liver allograft recipients-benefit of tacrolimus versus cyclosporine.
|
pubmed:affiliation |
Department of Internal Medicine, Division of Nephrology, University of Heidelberg, Germany. ralf_dikow@med.uni-heidelberg.de
|
pubmed:publicationType |
Journal Article,
Comparative Study
|